

Can anti-HIV drugs, Lopinavir and Ritonavir, be used to treat patients with severe COVID-19?





Source: Bars in Figure 3 indicate 95% confidence intervals. Results less than the lower limit of quantification of

polymerase-chainreaction (PCR) assay and greater than the limit of qualitative detection are imputed with 1 log10 copies per milliliter; results for patients with viralnegative RNA are imputed with 0 log10 copies per milliliter. Among the 199 patients, 130 (59 patients in the lopinavir—ritonavir group and 71 in the standard-care group) had virologic data that were used for viral load calculation, whereas the rest of the patients had undetectable viral RNA on throat swabs over the time. (Source: Cao et al., 2020 NEJM)

Results of a randomised, controlled, open-label trial involving hospitalised adult patients with confirmed SARS-CoV-2 infection were reported in a recent article in the New England Journal of Medicine. Patients were randomly assigned to receive either lopinavir—ritonavir twice a day for 14 days in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement. Laboratory-confirmed SARS-CoV-2 infected patients (n=199) underwent randomisation with 99 assigned to lopinavir—ritonavir and 100 to the standard-care group. Treatment with lopinavir—ritonavir did not improve time to clinical improvement; did not improve mortality and the proportion of patients with detectable viral RNA at various time points were similar to the standard of care group of patients. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of gastrointestinal adverse events. The authors conclude that "we found that lopinavir-ritonavir treatment did not significantly accelerate clinical improvement, reduce mortality, or diminish throat viral RNA detectability in patients with serious Covid-19."

Journal Article: Cao et al., 2020. <u>A Trial of</u> <u>Lopinavir-Ritonavir in Adults Hospitalized with Severe</u> <u>Covid-19.</u> NEJM

Article by Clive Gray